We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Is Innovation-Led Growth Driving ISRG's Revenues Above Procedures?
Read MoreHide Full Article
Key Takeaways
ISRG Q1 revenues rose 23% vs. 17% procedure growth, highlighting a widening monetization gap.
ISRG benefits from da Vinci 5, boosting pricing, utilization, and I&A revenue per procedure.
ISRG faces push-pull as premium pricing meets cost-sensitive markets and lower-cost system demand.
Intuitive Surgical’s (ISRG - Free Report) first-quarter 2026 results highlight a widening divergence between revenue growth (23%) and procedure growth (17%), signaling the increasing role of innovation-led monetization in its business model. This gap reflects not only volume expansion but also pricing power and a favorable product mix, particularly driven by the ramp-up of the da Vinci 5 platform.
A key driver is the premium pricing and higher system utilization of the da Vinci 5, which is accounting for a growing share of placements and usage. Management noted that revenue growth outpacing procedure growth is largely attributable to the differentiated value of the da Vinci 5 platform, which supports accretive pricing, greater integration and incremental trade-in activity. Supporting this trend, average selling prices rose to nearly $1.7 million, alongside an increase in instruments and accessories (I&A) revenue per procedure, partly driven by a higher mix of da Vinci 5 and SP procedures.
This dynamic reflects what management termed ‘innovation-led revenue growth’ — a model in which differentiated technology enables Intuitive Surgical to capture incremental value beyond procedure volumes. The company is effectively monetizing advanced features such as Force Feedback instrumentation, digital integration and AI-enabled capabilities, which enhance clinical outcomes and workflow efficiency, thereby justifying premium pricing.
The sustainability of this revenue-procedure spread will depend on market mix. Management acknowledged a “push and pull” dynamic — where premium innovation supports pricing in developed markets, but cost-sensitive geographies and procedures may require price concessions or lower-cost offerings, such as refurbished Xi systems.
The first-quarter result underscores a structural shift in ISRG’s growth model — from purely volume-driven expansion to a more value-based monetization strategy. While the current spread appears sustainable in the near term, its durability will hinge on continued innovation differentiation and the company’s ability to balance pricing power with global affordability dynamics.
Peer Updates
Abbott (ABT - Free Report) delivered modest top-line growth in the first quarter of 2026, with comparable sales rising 3.7% and EPS up 6%, better than market expectations. Revenue drivers were diversified, including new product launches (PFA catheters), strength in emerging markets pharmaceuticals (up 9%) and contributions from the Exact Sciences acquisition.
Procedure-linked businesses — particularly Medical Devices — remained strong, led by cardiovascular segments such as electrophysiology (up 13%) and heart failure (up 12%), indicating healthy underlying procedural volumes.
Diagnostics growth was constrained by a weaker respiratory testing season, highlighting sensitivity to episodic testing demand. Overall, Abbott’s growth was supported by procedure recovery, innovation and portfolio breadth, despite near-term diagnostic headwinds.
Boston Scientific (BSX - Free Report) delivered a solid first-quarter 2026 performance, with organic sales growth of 9.4% and revenues reaching $5.2 billion (+11.6% YoY), reflecting strong underlying procedural demand. Procedure volumes remained robust across key franchises, particularly in electrophysiology (+22%), cardiovascular (+11%) and neuromodulation (+15%), highlighting sustained adoption of minimally invasive therapies.
This growth was driven by innovation-led platforms such as FARAPULSE, WATCHMAN and interventional oncology technologies, alongside strong international momentum. However, some procedure softness emerged in WATCHMAN late in the quarter due to capacity and workflow constraints.
Overall, BSX’s revenues were supported by high procedure intensity, new product launches and global market expansion.
ISRG’s Price Performance, Valuation and Estimates
Shares of ISRG have lost 19.1% so far this year compared with an 11.4% decline for the industry.
Image Source: Zacks Investment Research
From a valuation standpoint, Intuitive Surgical trades at a forward price-to-earnings ratio of 46.59, above the industry average. But, it is still lower than its five-year median of 70.50. ISRG carries a Value Score of D.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for Intuitive Surgical’s 2026 earnings implies an 11.5% rise from the year-ago period’s level.
View the Zacks #1 Rank List
Image: Shutterstock
Is Innovation-Led Growth Driving ISRG's Revenues Above Procedures?
Key Takeaways
Intuitive Surgical’s (ISRG - Free Report) first-quarter 2026 results highlight a widening divergence between revenue growth (23%) and procedure growth (17%), signaling the increasing role of innovation-led monetization in its business model. This gap reflects not only volume expansion but also pricing power and a favorable product mix, particularly driven by the ramp-up of the da Vinci 5 platform.
A key driver is the premium pricing and higher system utilization of the da Vinci 5, which is accounting for a growing share of placements and usage. Management noted that revenue growth outpacing procedure growth is largely attributable to the differentiated value of the da Vinci 5 platform, which supports accretive pricing, greater integration and incremental trade-in activity. Supporting this trend, average selling prices rose to nearly $1.7 million, alongside an increase in instruments and accessories (I&A) revenue per procedure, partly driven by a higher mix of da Vinci 5 and SP procedures.
This dynamic reflects what management termed ‘innovation-led revenue growth’ — a model in which differentiated technology enables Intuitive Surgical to capture incremental value beyond procedure volumes. The company is effectively monetizing advanced features such as Force Feedback instrumentation, digital integration and AI-enabled capabilities, which enhance clinical outcomes and workflow efficiency, thereby justifying premium pricing.
The sustainability of this revenue-procedure spread will depend on market mix. Management acknowledged a “push and pull” dynamic — where premium innovation supports pricing in developed markets, but cost-sensitive geographies and procedures may require price concessions or lower-cost offerings, such as refurbished Xi systems.
The first-quarter result underscores a structural shift in ISRG’s growth model — from purely volume-driven expansion to a more value-based monetization strategy. While the current spread appears sustainable in the near term, its durability will hinge on continued innovation differentiation and the company’s ability to balance pricing power with global affordability dynamics.
Peer Updates
Abbott (ABT - Free Report) delivered modest top-line growth in the first quarter of 2026, with comparable sales rising 3.7% and EPS up 6%, better than market expectations. Revenue drivers were diversified, including new product launches (PFA catheters), strength in emerging markets pharmaceuticals (up 9%) and contributions from the Exact Sciences acquisition.
Procedure-linked businesses — particularly Medical Devices — remained strong, led by cardiovascular segments such as electrophysiology (up 13%) and heart failure (up 12%), indicating healthy underlying procedural volumes.
Diagnostics growth was constrained by a weaker respiratory testing season, highlighting sensitivity to episodic testing demand. Overall, Abbott’s growth was supported by procedure recovery, innovation and portfolio breadth, despite near-term diagnostic headwinds.
Boston Scientific (BSX - Free Report) delivered a solid first-quarter 2026 performance, with organic sales growth of 9.4% and revenues reaching $5.2 billion (+11.6% YoY), reflecting strong underlying procedural demand. Procedure volumes remained robust across key franchises, particularly in electrophysiology (+22%), cardiovascular (+11%) and neuromodulation (+15%), highlighting sustained adoption of minimally invasive therapies.
This growth was driven by innovation-led platforms such as FARAPULSE, WATCHMAN and interventional oncology technologies, alongside strong international momentum. However, some procedure softness emerged in WATCHMAN late in the quarter due to capacity and workflow constraints.
Overall, BSX’s revenues were supported by high procedure intensity, new product launches and global market expansion.
ISRG’s Price Performance, Valuation and Estimates
Shares of ISRG have lost 19.1% so far this year compared with an 11.4% decline for the industry.
Image Source: Zacks Investment Research
From a valuation standpoint, Intuitive Surgical trades at a forward price-to-earnings ratio of 46.59, above the industry average. But, it is still lower than its five-year median of 70.50. ISRG carries a Value Score of D.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for Intuitive Surgical’s 2026 earnings implies an 11.5% rise from the year-ago period’s level.
Image Source: Zacks Investment Research
The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.